CA125 screening after risk-reducing salpingo-oophorectomy: Are the titers too high, or is it all just too much?

Menopause

Volumn 18, Issue 2, 2011, Pages 123-124

  Bradford, Leslie S ^a   Schorge, John O ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN;

ANTIBODY TITER; CANCER SCREENING; EDITORIAL; GENE MUTATION; HUMAN; MENSTRUAL CYCLE; OVARY CANCER; PERITONEUM CANCER; POSTMENOPAUSE; PREMENOPAUSE; RISK REDUCING SALPINGOOOPHORECTOMY; SALPINGOOOPHORECTOMY; TRANSVAGINAL ECHOGRAPHY;

ADULT; BREAST NEOPLASMS; CA-125 ANTIGEN; CARCINOMA; FALLOPIAN TUBES; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; INCIDENCE; MEMBRANE PROTEINS; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; PERITONEAL NEOPLASMS;

EID: 79951575957     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31820246da     Document Type: Editorial

References (17)

1. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2009;113:957-966.
2. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-1130. (Pubitemid 36530000)
3. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302: 643-646. (Pubitemid 37310920)
4. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oopho-rectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-1622. (Pubitemid 34755669)
5. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophrectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008;26:1331-1337.
6. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005;23:7491-7496. (Pubitemid 46291812)
7. Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006;7:223-229. (Pubitemid 43286452)
8. ACOG Practice Bulletin No. 89: Elective and risk-reducing salpingo-oophorectomy. Obstet Gynecol 2008;111:231-241.
9. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006;296:185-192.
10. Skates S, Troiano R, Knapp RC. Longitudinal CA125 detection of sporadic papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 2003;13:693-696. (Pubitemid 38222616)
11. Schorge JO, Modesitt SC, Coleman RL, et al. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol 2010;119:7-17.
12. Van Altena AM, Holtsema H, Hendriks JC, Massuger LF, de Hullu JA. Cancer antigen 125 level after a bilateral salpingo-oophorectomy: what is the contribution of the ovary to the cancer antigen 125 level? Menopause 2011;18:133-137.
13. Bon GG, Kenemans P, Dekker JJ, et al. Fluctuations in CA125 and CA15-3 serum concentrations during spontaneous ovulatory cycles. Hum Reprod 1999;14:566-570. (Pubitemid 29097419)
14. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997;277: 997-1003. (Pubitemid 27142370)
15. Daly MB, Axilbund JE, Bryant E. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Cancer Netw 2006;4:156-176.
16. Levine DA, Argenta PA, Yee CJ, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 2003;21:4222-4227. (Pubitemid 46606192)
17. Greene MH, Piedmonte M, Alberts D, et al. A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev 2008;17:594-604. (Pubitemid 351469209)